INTRODUCTION
The etymological roots of pharmacovigilance are phar macy and vigilance from the Greek words Pharmakon = Drug and Latin = Vigilare, which mean "To keep awake or alert, to keep watch" and "To keep watch on drugs, in particular, their safety." The World Health Organization (WHO) defines pharmacovigilance as the pharmaco logical science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drugrelated problems.
1,2 Consumers, health care professionals (HCPs), pharmaceutical compa nies, and global regulatory agencies play a significant role in the process of pharmacovigilance. Pharmacovigilance has evolved from largely a recordkeeping function, where the purpose was mainly to ensure the processing and submission of individual case reports, to the present, where it now focuses on proactively identifying safety issues and taking appropriate actions to minimize and mitigate risk to the patients. This review highlights the process of pharmacovigilance in adverse event reporting and its impact on patient management and safety.
Pharmacovigilance: Past and Present
In the early 1900s, the US Food and Drug Administration (FDA) focused mainly on regulatory enforcement on foods that were thought to pose a greater public health problem. However, in 1938, the Food Drug and Cosmetic Act brought cosmetics and medical devices under the control of the FDA and required that drugs be labeled with adequate directions for safe use. 3 A new break through in the field of pharmacovigilance happened after a single episode in 1937, when sulfanilamide was used for the treatment of streptococcal infections as syrup. It contained diethylene glycol as solvent. This syrup was responsible for the death of 105 patients, and out of them, 34 were children and 71 were adults. This tragedy caused the American Congress to approve the Food, Drug, and Cosmetic Act in 1938, under which pharmaceutical product manufacturers were directed to show scientific evidences of the safety of the drugs before marketing. 4 The thalidomide disaster is a milestone in the origin and further development of pharmacovigilance. Thalidomide was introduced in 1957 and was widely prescribed as a treatment for morning sickness, but there were reports of a congenital abnormality in fetus called as phocomelia. Thus, the words thalidomide and birth defects became permanently linked as a result of consumption of thalido mide as a sedative in pregnancy. In 1962, after multiple reports of phocomelia, it was discontinued. 5 Thus, in 1962, the Kefauver Harris amendment was approved, which required scientific evidences of efficacy and safety of drugs before marketing in humans. 6 At present, the database contains more than four million ADR reports. 7 The European Medicines Agency (EMA) was founded in 1995, and it is a decentralized body of the European Union (EU). Its main responsibility is protec tion and promotion of public and animal health through the evaluation and supervision of medicines for human and veterinary use. The EMA can be considered the hub of a European medicines network, comprising over 40 national competent authorities, the European Commis sion, the European Parliament, and a number of other decentralized EU agencies. 8 The agency works closely with its European partners to build the best possible regulatory system for medicines for Europe and to protect the health of its citizens. Flow Chart 1 explains the flow of ADRs at regional, national, and international level.
History of Pharmacovigilance in India
The origin of pharmacovigilance in India goes back to 1986, when a formal ADR monitoring system consisting of 12 regional centers, each covering a population of 50 million, was proposed. 10 to NCC via the same software. Some AMCs are also responsible for providing training and technical support at the regional level. The PvPI started with the enrol ment of >22 AMCs across the country in 2010, which has increased to 90 by the end of 2012, 60 of which are phase I AMCs and 30 are phase II AMCs. All the 90 AMCs are categorized into four zones, i.e., North, South, East, and West, as per zonal offices of CDSCO in India and are functioning under the NCC. There are more than 2,000 pharmacy colleges, 90 Institute of PharmD, more than 200 dental institutes, and more than 320 nursing institutes all over India. All PharmD, pharmacy practice, dental, and paramedical colleges are associated with patient care by providing safe and effective medication. For robust pharmacovigilance, these colleges will be included as AMCs under this program in the years to come. There are more than 360 MCIapproved medical colleges in India, of which 194 colleges are private. All MCIapproved col leges and Pharmacy Council of Indiaapproved pharmacy colleges having pharmacy practice and PharmD will be included in PvPI through proper channel. All MCI approved medical colleges and hospitals in the program covering north, south, east, and west of India will be enrolled, and ultimately, all government and corporate hospitals will be enrolled in the program covering entire India (Flow Chart 2).
Aims of Pharmacovigilance Program
It is due to pharmacovigilance program 14, 15 The monitoring of medicine safety in countries where there is no regulatory or safety monitoring system in place, or in remote areas with little or no health care surveillance or infrastructure, has been identified as a matter for concern. The problems are especially apparent in situations that involve the use of medicines in specific communities, e.g., for the treatment of tropical diseases, such as malaria, leishmaniasis, and schistosomiasis and for the treatment of human immunodeficiency virus/acquired immune deficiency syndrome and tuberculosis. 21 The WHO recommends that pharmacovigilance should be a priority for every country with public health disease control programs.
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• Drug utilization studies (DUSs): Drug utilization pat terns are a major determinant in drug safety. For instance, the use of injectable medicines is more common in developing countries. 23 Direct advertis ing to the consumer of prescription medicines has become commonplace in many countries. With this information, patients feel more able to make their own therapeutic decisions, without assistance from the doctor or pharmacist. The result has been increas ing selfmedication, licit and illicit sale of medicines over the Internet, and overprescribing by doctors on patients' demand. This has had considerable effect on increased prescribing of drugs. 24 Such public health programs, however, need not focus only on patients but could be used for the benefit of the general public as well. Such awareness building and educational initiatives should also include children and elderly populations and could be greatly facilitated through partnerships with the media, educational institutions, and governmental and NGOs. The success of WHO International Drug Monitoring Programs is entirely dependent on the contributions of national pharma covigilance centers. 25 Thus, pharmacovigilance has its importance in DUS by bridging more closely with other areas, such as public health, rational use of drugs, evidencebased drug use, pharmacoeconomics, ecopharmacovigilance, and pharmacogenetics.
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IMPACT OF PHARMACOVIGILANCE IN PATIENT TREATMENT
Knowledge of pharmacovigilance has improved the knowledge of the treating physician about various drugrelated events. The various benefits are as follows.
Impact on Chronic Kidney Disease/ End-Stage Renal Disease Treatment
Patients with chronic kidney disease (CKD) and endstage renal disease have significant challenges and complex therapeutic regimens. The presence of multiple comor bidities, such as cardiovascular disease, hypertension, and diabetes, requires the use of a variety of pharmaceuti cal interventions in addition to those needed to manage renal insufficiency. 27 Adding to this complex situation is the impact of chronic renal replacement therapy, which has its own set of adverse effects, but where drug effects may play either a causative role or may interact with an evolving complication. The impact of a drug safety issue in a patient with endstage renal failure may operate through different mechanisms and could include:
• Direct patient harm from the clinical sequelae of the adverse event.
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• An interaction with the dialysis therapy itself (e.g., the interaction of angiotensinconverting enzyme inhibitors with specific polyacrylonitrile hemodialysis membranes, causing an acute hypersensitivity reaction).
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• The risk of intravenous immunoglobulin in inducing renal failure as was evident from case series studies. 30 Since information related to the use of drugs in the CKD/dialysis population is at best limited, it is impor tant that nephrologists and other health care workers managing patients with endstage renal failure should understand the concept and implementation of pharma covigilance. This will contribute to enhanced patient safety for this highrisk population and mirror the drive by nephrology organizations to develop patient safety indicators to improve CKDspecific treatment.
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Impact on Other Clinical Situations
• Withdrawal of a specific lot of the peritoneal dialysis (PD) solution, Nutrineal™ (Baxter Healthcare Corporation, Deerfield, IL, USA), which occurred in Europe in October 2010. 32 Baxter began receiving a number of reports of aseptic peritonitis associated with one specific lot of Nutrineal. While the reporters informed Baxter of the peritonitis, many gave extremely limited details, providing no information on laboratory investigations, minimal information on whether the patient improved upon discontinuation of the Nutrineal, not providing information on other PD solutions that may have played a role in the adverse event, and not confirming the specific lot of Nutrineal in use at the time of the events. The lack of such details made it extremely challenging to analyze this signal; however, as further details were collected during followup calls to HCPs, Baxter was able to identify the lot association and take necessary action to withdraw this lot from the market.
• Icodextrin and device interaction: Extraneal™ (icodex trin) (Baxter Healthcare Corporation) is a PD solution containing the colloid osmotic agent icodextrin, a starchderived watersoluble glucose polymer. While Extraneal was closely monitored and assessed during clinical trials, an unanticipated, rare adverse event did not emerge until Extraneal was used by a larger population. Icodextrin, the osmotic agent in Extraneal, is metabolized into oligosaccharides including maltose and other higher molecular weight molecules. Certain glucometers are considered "nonspecific" and measure not only glucose but also metabolites, such as maltose. The presence of maltose can lead to falsely elevated glucose readings, 33, 34 which could in turn lead to the administration of more insulin than needed in patients using these glucometers. Administration of more insulin than needed can cause hypoglycemia, which may lead to loss of consciousness, coma, neurologic damage, and death. Additionally, falsely elevated blood glucose measurements due to maltose inter ference may mask true hypoglycemia, which left untreated can result in similar consequences. Falsely elevated glucose levels may be measured up to 2 weeks following cessation of icodextrin therapy. This particu lar issue did not occur in the Extraneal clinical trials, but was identified as Baxter began receiving cases of falsely elevated glucose readings after product launch. This lifethreatening issue is best exemplified by a published case report of a 59yearold patient on Extraneal who was admitted for an elective procedure. 35 During the preoperative period, she communicated to the HCPs that, due to her Extraneal use, she required the use of a specific glucometer. Unfortunately, when the patient was transferred postoperatively to the intensive care unit (ICU), this message was not transferred with her. The readings on the nonspecific glucose handheld monitors in the ICU provided an overestimation of the glucose level, leading to the administration of too much insulin. The patient developed hypoglycemic encephalopathy and eventually died at an extended care nursing facility.
• Quinolones and tendon rupture: The use of quinolone antibiotics has been associated with the development of tendon rupture in animal studies. This risk was identified largely based on postmarketing rather than clinical trial data and illustrates an additional impor tant point. Many clinicians may not consider reporting a tendon rupture to the manufacturer of an antibiotic, believing that it is "biologically not possible," yet this adverse event was first reported in medical journals as case reports seen in the postmarketing setting. This adverse event has led to boxed warnings in all quino lone labels. This is of particular relevance in dialysis patients since quinolone use is not uncommon in this population.
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• Drug-induced hepatic failure: It is a frequent cause of withdrawals of drugs from the market. Troglitazone used in diabetes is an example. It was withdrawn fol lowing cases of hepatic toxicity found in postmarketing surveillance. Hepatic reactions are rare, and therefore difficult to detect prior to marketing of a drug. A trial involving 30,000 patients would be required to detect with reasonable certainty a reaction occurring in one patient in 10,000. 37 As a result, postmarketing surveil lance for hepatic reactions to new drugs is crucial. Druginduced liver disease is a serious reaction and should be reported to the pharmacovigilance center immediately. This applies also to new drugs with known history of hepatotoxicity.
38
CONCLUSION
Thus, it can be concluded that pharmacovigilance is an important tool in ensuring patient safety as by reporting the ADRs, the patient morbidity and mortality can be reduced. This also enhances the knowledge of prescribers about drugrelated events, and thus appropriate modifi cation in the treatment can be done to benefit the patients.
